Total submissions: 10
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000668057 | SCV000792601 | likely pathogenic | Fanconi anemia complementation group A | 2017-07-05 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000813603 | SCV000953969 | pathogenic | Fanconi anemia | 2024-09-16 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln286*) in the FANCA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in FANCA are known to be pathogenic (PMID: 19367192). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with Fanconi anemia (PMID: 10094191, 12697994). ClinVar contains an entry for this variant (Variation ID: 552738). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Ce |
RCV001092317 | SCV001248755 | pathogenic | not provided | 2024-09-01 | criteria provided, single submitter | clinical testing | FANCA: PVS1, PM2, PM3 |
Centre for Mendelian Genomics, |
RCV000668057 | SCV001370198 | pathogenic | Fanconi anemia complementation group A | 2019-02-20 | criteria provided, single submitter | clinical testing | This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PVS1,PM2,PP5. |
Institute for Clinical Genetics, |
RCV001092317 | SCV002010162 | pathogenic | not provided | 2021-11-03 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000668057 | SCV002024571 | likely pathogenic | Fanconi anemia complementation group A | 2019-04-26 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000668057 | SCV004196624 | likely pathogenic | Fanconi anemia complementation group A | 2022-06-21 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000668057 | SCV005639510 | likely pathogenic | Fanconi anemia complementation group A | 2024-05-20 | criteria provided, single submitter | clinical testing | |
Leiden Open Variation Database | RCV000668057 | SCV001425911 | pathogenic | Fanconi anemia complementation group A | 2020-02-28 | no assertion criteria provided | curation | Curator: Arleen D. Auerbach. Submitter to LOVD: Arleen D. Auerbach. |
Prevention |
RCV004742563 | SCV005343157 | pathogenic | FANCA-related disorder | 2024-03-12 | no assertion criteria provided | clinical testing | The FANCA c.856C>T variant is predicted to result in premature protein termination (p.Gln286*). This variant was reported in an individual with Fanconi anemia (Wijker et al 1999. PubMed ID: 10094191). This variant has not been reported in a large population database, indicating this variant is rare. Nonsense variants in FANCA are expected to be pathogenic. This variant is interpreted as pathogenic. |